1. Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention
- Author
-
Fina A S Kurreeman, M. P. M. de Maat, PS Monraats, René A. Tio, Daniel Eefting, Johannes Waltenberger, FR de Vries, R. J. de Winter, Paul H.A. Quax, V. D. K. D. Sewgobind, P. A. Doevendans, Twj Huizinga, A. van der Laarse, Johan Wouter Jukema, Douwe Pons, Aeilko H. Zwinderman, E. E. van der Wall, Rune R. Frants, Internal Medicine, Hematology, Amsterdam Public Health, Epidemiology and Data Science, Amsterdam Cardiovascular Sciences, Cardiology, and TNO Kwaliteit van Leven
- Subjects
Oncology ,Male ,Biomedical Research ,genetic association ,genotype ,medicine.medical_treatment ,LIPOPOLYSACCHARIDE ,genetic risk ,disease marker ,Restenosis ,Risk Factors ,genetic variability ,genetic polymorphism ,Angioplasty, Transluminal, Percutaneous Coronary ,TRANSCRIPTION ,Prospective Studies ,Angioplasty, Balloon, Coronary ,Prospective cohort study ,Promoter Regions, Genetic ,cysteine ,3' Untranslated Regions ,Genetics (clinical) ,TUMOR-NECROSIS-FACTOR ,Genetics ,HUMAN POLYMORPHONUCLEAR LEUKOCYTES ,adult ,pathogenesis ,article ,Middle Aged ,Clopidogrel ,in-stent restenosis ,Interleukin-10 ,aged ,female ,Treatment Outcome ,priority journal ,risk factor ,Drug-eluting stent ,Health ,IL-10 ,hypothesis ,Female ,Promoter Regions (Genetics) ,GENETIC INFLUENCE ,alanine ,MESSENGER-RNA ,drug eluting stent ,medicine.drug ,cardiovascular risk ,medicine.medical_specialty ,gene locus ,Genotype ,Immunology ,heart infarction ,ticlopidine ,DNA flanking region ,Biology ,Coronary Restenosis ,restenosis ,coronary artery bypass graft ,PCl ,Internal medicine ,medicine ,Genetic predisposition ,Humans ,controlled study ,Genetic Predisposition to Disease ,human ,MENINGOCOCCAL DISEASE ,POLYMORPHISMS ,Aged ,Inflammation ,clopidogrel ,Polymorphism, Genetic ,percutaneous coronary intervention ,DNA microarray ,Percutaneous coronary intervention ,CYTOKINE PRODUCTION ,medicine.disease ,major clinical study ,gene linkage disequilibrium ,confidence interval ,Relative risk ,Conventional PCI ,interleukin 10 ,genetic predisposition ,glycine - Abstract
Genetic factors appear to be important in the process of restenosis after percutaneous coronary intervention (PCI), as well as in inflammation, a pivotal factor in restenosis. An important mediator in the inflammatory response is interleukin (IL)-10. Our aim was to study whether genetic variants in IL-10 predispose to the risk of restenosis. The GENetic DEterminants of Restenosis (GENDER) study included 3104 patients treated with successful PCI. Target vessel revascularization (TVR) was chosen as primary end point. Genotyping of the -2849G/ A, -1082G/ A, -592C/A and +4259A/G polymorphisms of the IL-10 gene was performed by MassArray platform. After adjusting for clinical variables, three polymorphisms significantly increased the risk of restenosis (-2849AA: relative risk (RR), 1.7, 95% confidence interval (CI), 1.2-2.5; -1082AA: RR, 1.4, 95% CI, 1.1-1.8 and +4259GG: RR, 2.0, 95% CI, 1.4-2.8). To further exclude possible involvement of neighboring genes due to LD in the IL-10 locus, additional polymorphisms were genotyped. The results reveal that association of the IL-10 gene with restenosis is independent of flanking genes. Our findings demonstrate that IL-10 is associated with restenosis and therefore support the hypothesis that anti-inflammatory genes also may be involved in developing restenosis. Furthermore, they may provide a new targeting gene for drug-eluting stents.
- Published
- 2006